{
  "ticker": "NYR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02977427",
  "id": "02977427",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250806",
  "time": "0938",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250806/pdf/06ml86xg3cbxlk.pdf",
  "summary": "### **Material Information Summary**  \n\n- **Phase I Clinical Trial Results:**  \n  - Final safety review completed; **no dose-limiting safety signals** observed.  \n  - **Xolatryp\u2122 well tolerated** across all cohorts (48 participants: 40 drug, 8 placebo).  \n  - **Linear pharmacokinetics** confirmed with predictable dosing.  \n  - **Topline results expected September 2025 quarter**.  \n\n- **Next Steps:**  \n  - **Phase IIa trial** planned for **early 2026** in acute myocardial infarction patients.  \n  - Ethics submission for Phase IIa targeted for **November 2025**.  \n\n- **Preclinical Highlights (Reiterated):**  \n  - **Cardioprotection:** 42% efficacy in 3-hour treatment (May 2025 data).  \n  - **Neuroprotection:** Statistically significant results in traumatic brain injury (April 2025).  \n\n*No capital markets or liquidity-impacting updates identified.*",
  "usage": {
    "prompt_tokens": 2057,
    "completion_tokens": 203,
    "total_tokens": 2260,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-05T23:50:39.075782"
}